Ophthalmol Ther 2022 1113091332 httpsdoiorg101007s4012302200513y REVIEW Prevalence Characteristics Dry Eye Disease After Cataract Surgery A Systematic Review MetaAnalysis Maria Miura Takenori Inomata Masahiro Nakamura Jaemyoung Sung Ken Nagino Akie Midorikawa Inomata Jun Zhu Keiichi Fujimoto Yuichi Okumura Kenta Fujio Kunihiko Hirosawa Yasutsugu Akasaki Mizu Kuwahara Atsuko Eguchi Hurramhon Shokirova Akira Murakami Received February 9 2022 Accepted April 4 2022 Published online May 9 2022 cid2 The Authors 2022 ABSTRACT Dry eye disease DED cataract surgery associated risk factors causing wide range fof heterogeneous symptoms including decreased quality vision This sys tematic review metaanalysis aimed deter prevalence characteristics DED cataract surgery We searched PubMed EMBASE included studies patients DED cataract surgery January 2011 June 2020 Studyspeciﬁc estimates DED prevalence rates cataract surgery patients preexisting DED combined onegroup metaanalysis randomeffects model We included 36 studies published 2013 2020 We included metaanalysis DED prevalence cataract surgery Overall 374 95 CI 226523 206775 patients preexisting DED developed DED cataract surgery The risk T Inomata cid2 K Nagino cid2 A MidorikawaInomata cid2 A Eguchi Department Hospital Administration Juntendo University Graduate School Medicine Tokyo Japan M Nakamura Department Bioengineering Graduate School Engineering Precision Health The University Tokyo Tokyo Japan J Zhu Department Ophthalmology Subei Peoples Hospital Afﬁliated Yangzhou University Yangzhou Jiangsu Province China M Miura cid2 T Inomata cid2 J Sung cid2 J Zhu cid2 K Fujimoto cid2 Y Okumura cid2 K Fujio cid2 K Hirosawa cid2 Y Akasaki cid2 M Kuwahara cid2 H Shokirova cid2 A Murakami Department Ophthalmology Juntendo University Graduate School Medicine 211 Hongo BunkyoKu Tokyo 1130033 Japan email tinomajuntendoacjp M Miura cid2 T Inomata cid2 M Nakamura cid2 K Fujimoto cid2 Y Okumura cid2 K Fujio cid2 K Hirosawa cid2 Y Akasaki cid2 M Kuwahara cid2 A Murakami Department Digital Medicine Juntendo University Graduate School Medicine Tokyo Japan T Inomata cid2 A Murakami Department Ophthalmology Juntendo University Faculty Medicine Tokyo Japan T Inomata cid2 Y Okumura Department Strategic Operating Room Management Improvement Juntendo University Graduate School Medicine Tokyo Japan 1310 Ophthalmol Ther 2022 1113091332 factors DED cataract surgery included age female sex systemic diseases systemic medica tions psychiatric conditions preexisting DED meibomian gland dysfunction preservatives eye drops surgery techniques lifestyle DED severity peak occurred 1 day postoperatively persisted 112 months following cat aract surgery consistent followup DED warranted 1 month catar act surgery Topical administration preserva tivefree diquafosol tetrasodium solution preoperative meibomian gland treatment effective preventing treating DED follow ing cataract surgery As onethird patients develop DED cataract surgery care ful DED management treatment needed cataract surgery improve satisfaction vision quality surgery Characteristics Keywords Cataract Dry eye disease Metaanalysis Prevalence Risk factors review DED MGD Systematic Meibomian gland dysfunction Key Summary Points This largescale systematic review metaanalysis aimed comprehensively present dry eye disease DED prevalence associated risk factors speciﬁcally patients undergone cataract surgery preexisting DED A wide range data surgeryspeciﬁc factors analyzed surgical techniques postsurgical treatment contributed broader understanding DED pathogenesis This study identiﬁed 374 95 CI 226523 206775 patients preexisting DED developed DED following cataract surgery The timelines symptom severity according different measurement intervals duration compiled yielding accurate pattern DED progression following cataract surgery A major portion included studies based Asian population calls veriﬁcation generalizability results INTRODUCTION Cataract surgery increasingly prevalent ophthalmic procedure owing aging soci ety 1 2 Although yields excellent results patients develop postoperative dis orders dry eye disease DED 35 symptoms foreign body sensation ocular fatigue 6 7 This nega tively impacts quality vision QOV work productivity economic repercus sions 8 warranting preventative manage ment strategies DED cataract surgery 9 including dryness established The pathogenesis DED cataract sur gery remains unclear resulting lack evi dencebased 9 Moreover systematic largescale studies DED following cataract surgery individuals preexisting DED comprehensively elucidate risk factors duration treatment treatment This systematic review metaanalysis aimed summarize current evidence identify prevalence characteristics periop erative risk factors treatment preventative measures DED cataract surgery METHODS Outcomes surgery DED prevalence cataract assessed reviewing systematically evaluated characterized studies focusing risk fac tors duration treatment DED manage ment cataract surgery From relevant studies extracted pre postoperative results DED examinations including Ocular Surface Disease Index OSDI 1012 tear ﬁlm breakup time TFBUT Schirmers I test corneal Ophthalmol Ther 2022 1113091332 1311 TOV tear osmolarity values ﬂuorescein staining CFS tear meniscus height TMH 13 severity peak postoperative disease dura tion In reports multiple severity peaks different parameters parameter peaks chosen Priority given subjective symptoms OSDI interparameter differences Search Strategy We retrieved articles published January 1 2011 June 9 2020 combining search terms cataract AND dry eye NOT review key electronic bibliographic data bases PubMed EMBASE The search ducted June 2020 We followed Preferred Reporting Items Systematic Reviews MetaAnalyses reporting guidelines 14 Table 1 presents inclusion exclusion criteria The search results compiled EndNote X932 software Clarivate Analytics Philadel phia To maintain quality standards reporting systematic reviews metaanalyses observational studies 15 retrieved arti cles screened researchers MM TI independently assessed eligible text articles consensus Data Extraction Two independent reviewers MM TI extracted data eligible articles standardized data extraction sheets crosschecked results Interreviewer dis agreements resolved discussions reviewer JS The following data extracted ﬁrst author publication date study type country sample size followup time cataract surgery deﬁnition DED The following characteristics asses sed patients DED cataract surgery age sex ocular ﬁndings DED prevalence peak DED severity duration DED cataract surgery Ocular ﬁndings assessed basis OSDI TFBUT CFS Schir mers I test TMH TOV presence mei bomian gland dysfunction MGD Figure 1a Table 1 Study inclusion exclusion criteria Inclusion criteria Population Patients underwent cataract surgery Study design Retrospective studies crosssectional casecontrol studies prospective studies Outcomes Assessment following outcomes prevalence DED cataract surgery TFBUT TMH Schirmers I test CFS TOV MGD presence Procedures The procedure phacoemulsiﬁcation femtosecond laserassisted cataract surgery Exclusion criteria Clinical guidelines consensus documents reviews systematic reviews conference proceedings Patients history ophthalmic surgery ocular surface disorders History intracapsular extracapsular cataract extraction Animalbased studies Preprinted articles Conference abstracts CFS corneal ﬂuorescein staining DED dry eye disease MGD meibomian gland dysfunction TFBUT tear ﬁlm breakup time TMH tear meniscus height TOV tear osmolarity values summarizes identifying published studies selection process Statistical Analyses Studyspeciﬁc estimates prevalence rates DED cataract surgery combined onegroup metaanalysis random effects model OpenMetaAnalyst version 121114 available httpwwwcebm browneduopenmeta 16 Subgroup analyses performed studies reported speciﬁc outcome 1312 Ophthalmol Ther 2022 1113091332 Fig 1 Flowchart systematic reviewPRISMA ﬂow diagram b DED prevalence cataract surgery Forest plot prevalence rates DED cataract surgery patients preexisting DED For study symbol size corresponds sample size DED dry eye disease PRISMA Preferred Reporting Items Systematic Reviews MetaAnalyses Ethics DED Prevalence After Cataract Surgery This article based previously conducted studies contain new studies human participants animals performed authors RESULTS The database search identiﬁed 280 articles Fig 1a Three additional articles selected reference lists included articles 1719 reviewed basis title abstract A total 247 articles exclu ded low relevance article type consensus documents clinical reviews systematic reviews conference proceedings Finally 36 articles included systematic review included metaanalysis estimate prevalence DED cataract surgery patients preexisting DED guidelines Study Characteristics Demographic Features Table 2 presents results included studies published Novem ber 12 2013 June 3 2020 The details include study type country sample size follow time cataract surgery deﬁnition DED DEDrelated clinical metrics OSDI TFBUT Table 2 presents DED prevalence patients preexisting DED Among 775 patients preexisting DED identiﬁed studies 6 18 20 23 30 32 37 50 51 206 266 individuals developed DED catar act surgery A onegroup metaanalysis stud ies reporting DED prevalence cataract surgery 6 18 20 23 30 32 37 50 51 yielded 374 prevalence rate 206775 95 CI 226523 Fig 1b Severity Peak Duration DED After Cataract Surgery cataract severity peak Table 2 summarizes duration DED surgery Although early postoperative ocular surface changes began recover month cataract surgery 38 studies reported DED parameters including subjective symp toms TFBUT CFS tear secretion volume MGD recover baseline values end study indicated study iod The peaks DED severity usually occur red 1 week cataract surgery reported values ranged 1 month 1 year 6 17 19 23 26 27 2935 37 40 41 44 57 58 Notably 22 articles 1 month reported severity peak Ophthalmol Ther 2022 1113091332 1313 g n t s x e e r P D E D 0 2 9 0 A N 0 0 1 8 5 8 5 0 0 1 2 9 1 2 9 1 D E D f o n o t n ﬁ e D x e S F M 5 2 I D S O 1 3 1 6 A N 1 3 7 2 A N 7 2 3 5 A N 2 3 1 0 6 t c r t c y r e g r u s D S n e m r e t f e m t e z s e g A p u w o l l o F e l p m S y r t n u o C e p y t y d u t S n o t c l b u P e c r u o S e t d s e d u t s d e d u l c n e h t f o s c t s r e t c r h C 2 e l b T 3 8 2 7 6 7 1 1 3 8 6 5 8 6 8 6 1 8 5 8 6 s e y e M 3 2 9 2 9 d n l h T y d u t s e v t p r c s e d e v t c e p s o r P r e b m e v o N n w u s t e s K s e y e 3 1 0 2 0 2 l t e M 3 8 5 8 4 e r o K s e r e s e s c l n o t v r e s b o e v t c e p s o r P 4 1 0 2 e n u J l t e n H s e y e 1 2 M 2 0 8 0 8 e r o K y d u t s d e l l o r t n o c d e z m o d n R 5 1 0 2 l r p A 2 2 l t e e e J M 4 2 2 9 1 6 9 y e k r u T y d u t s e v t c e p s o r t e R 5 1 0 2 e n u J y k n t e C s e y e 7 1 l t e 0 0 0 1 0 I D S O A N 1 4 9 5 6 2 5 A N 4 2 A N 8 2 4 2 7 3 1 2 7 6 0 0 2 r e t r c c t s o n g d e s e n p J e h T 1 6 6 7 0 0 1 3 4 3 4 A N 0 3 3 1 0 0 1 4 6 4 6 7 0 0 2 r e t r c c t s o n g d S W E D e h T 9 1 5 4 9 2 5 8 2 4 3 8 1 7 0 0 2 r e t r c c t s o n g d S W E D e h T 7 2 1 2 9 5 8 0 6 1 0 1 8 1 7 1 8 2 1 7 8 3 1 0 5 6 0 6 2 4 6 0 9 7 6 6 M 2 M 1 s e y e s e y e 0 0 1 0 0 1 s e y e 7 3 1 7 3 1 d n I y d u t s l n o t v r e s b o e v t c e p s o r P r e b o t c O l t e u h S n g s e d l e l l r p t n e r r u c n o c h t w l r t 5 1 0 2 3 2 l t e 5 1 0 2 9 1 n h C d e z m o d n r n o n e v t u c e s n o c e v t c e p s o r P r e b m e c e D 6 l t e u Y y d u t s t r o h o c e v t r p m o c 5 1 0 2 M 3 2 5 2 5 n p S y d u t s t r o h o c l n o t v r e s b o e v t c e p s o r P r e b o t c O z e l z n o G s e y e 6 1 0 2 l t e s e M 5 2 M 3 3 4 3 4 e r o K s e r e s e s c l n o t v r e s b o e v t c e p s o r P r e b m e t p e S l t e m K s e y e 6 1 0 2 6 2 M 2 8 4 4 3 e r o K y d u t s l n o t v r e s b o e v t c e p s o r P r e b o t c O l t e k r P s e y e 6 1 0 2 7 2 M 3 4 6 4 6 e r o K s e r e s e s c l n o t v r e s b o e v t r p m o c e v t c e p s o r t e R y r u r b e F 9 2 l t e e e L 0 8 5 0 n o d e s b D E D f o s m o t p m y s d l M 0 3 8 2 6 9 5 M 2 8 5 8 5 d n I d e l l o r t n o c d e z m o d n r e v t c e p s o r p r e t n e c e l g n S r e b o t c O r d n e v e D 8 2 s e y e 7 1 0 2 1314 Ophthalmol Ther 2022 1113091332 g n t s x e e r P D E D D E D f o n o t n ﬁ e D x e S F M 7 9 6 4 2 9 9 1 3 3 4 2 0 3 6 0 0 2 r e t r c c t s o n g d e s e n p J e h T 4 3 2 0 5 6 0 A N 8 2 7 3 3 3 1 0 6 8 r e t r c c t s o n g d S W E D S O F T e h T 9 2 1 3 D S n e m r e t f e m t e z s e g A p u w o l l o F e l p m S y r t n u o C e p y t y d u t S n o t c l b u P e c r u o S e t d d e u n t n o c 2 e l b T 5 7 9 1 7 7 7 8 1 7 3 2 7 8 6 t c r t c y r e g r u s M 2 s e y e 3 3 4 3 3 4 n p J 1 s e s h p y d u t s e v t c e p s o r p e v t u c e s n o c o w T 7 1 0 2 y M l t e e k y M y r e g r u s t c r t c e r o f e b m o r f y d u t s l n o t v r e s b O n e p o d e z m o d n R 2 y r e g r u s r e t f s k e e w r u o f o t s k e e w e v t r e p o t s o p 8 o t 4 m o r f y d u t s l e b l 0 3 M 2 5 6 5 6 n p J l r t l c n l c d e z m o d n R r e b m e t p e S l t e o t K s e y e 7 1 0 2 1 3 M 1 0 6 4 4 n h C s e r e s e s c l n o t n e v r e t n e v t c e p s o r P 7 1 0 2 y l u J l t e u f u s u Y 8 2 7 0 0 2 s e y e 2 3 0 0 1 4 9 4 9 s h t n o m 6 r e v o r o f I D S O n o d e s B 4 3 0 6 s r e m r h c S s 0 1 n h t s s e l T U B F T r e p m m 0 1 n h t s s e l e r o c s t s e t l e n r o c f o e c n e s e r p e h t d n n m 5 e g m d 8 3 6 c t s o n g d l p u o r G y g o o m l h t h p O 9 4 1 5 9 n o t c o s s A l c d e M e s e n h C e h T 5 5 4 9 3 1 0 2 r e t r c A N 6 3 2 1 I D S O 4 5 2 6 0 0 5 0 s u s n e s n o C n e p o r u E Y E S S I D O e h T 4 2 6 2 8 3 4 1 0 2 r e t r c c t s o n g d p u o r G 8 5 1 4 3 6 7 9 2 9 6 7 0 1 3 6 6 4 8 6 0 6 0 9 1 1 0 6 e r o c s 5 e r n n o t s e u Q e y E y r D 3 5 6 6 8 7 2 7 M 6 9 3 M 3 4 9 4 9 e r o K y d u t s d e z m o d n r l e b l n e p o e v t c e p s o r P 7 1 0 2 t s u g u A 3 3 l t e u C M 1 M 3 s e y e s e y e 9 4 1 9 4 1 s e y e 6 1 1 6 1 1 n h C d e z m o d n r s u o u n t n o c n g s e d l e l l r p e v t c e p s o r P r e b m e c e D 4 3 l t e e H y d u t s d e l l o r t n o c 7 1 0 2 e r o K y d u t s l n o t v r e s b o e v t c e p s o r P 8 1 0 2 e n u J l t e o h C 5 3 w 6 0 5 0 5 d n I y d u t s e v t c e p s o r P 8 1 0 2 e n u J l t e l h o K s e y e s e y e 9 1 1 9 1 1 A S U t r o h o c e v t c e p s o r P r e b m e c e D l t e n n j S 8 1 0 2 8 1 7 3 Ophthalmol Ther 2022 1113091332 1315 g n t s x e e r P D E D D E D f o n o t n ﬁ e D x e S F M 0 0 0 3 0 m m 0 1 B t s e t I s r e m r h c S 1 7 1 1 C S F C s 5 B T U B F T 9 2 1 n g e r o f s s e n y r d s h c u s s m o t p m y s g n n r u b d n n o t s n e s y d o b n o t s n e s A N A N 2 8 8 9 0 7 3 0 0 0 1 6 0 1 6 0 1 A N 6 1 1 2 A N 6 5 0 5 0 8 3 0 n o t c o s s A l c d e M e s e n h C e h T 6 1 2 2 c t s o n g d l p u o r G y g o o m l h t h p O 3 1 0 2 r e t r c D S n e m r e t f e m t e z s e g A p u w o l l o F e l p m S y r t n u o C e p y t y d u t S n o t c l b u P e c r u o S e t d d e u n t n o c 2 e l b T 6 2 1 1 9 6 3 8 7 2 7 0 2 1 1 3 7 0 5 2 3 6 7 8 6 2 7 t c r t c y r e g r u s M 3 s e y e 0 0 3 3 3 2 w 6 s e y e 0 8 1 0 8 1 n h C l r t d e z m o d n r r e t n e c e l g n s e v t c e p s o r P r e b o t c O l t e o h S 8 1 0 2 0 4 e c e e r G l r t d e z m o d n r r e t n e c t l u m e v t c e p s o r P y r u r b e F l t e t n o t N 9 1 0 2 1 4 M 1 4 7 7 3 v t L y d u t s e v t c e p s o r P r e b m e t p e S l t e s n s k l E M 3 s e y e s e y e 6 0 1 6 0 1 n h C l r t l c n l c d e z m o d n r e v t c e p s o r P 9 1 0 2 l r p A l t e g n o S 3 4 8 1 0 2 2 4 s e y e M 3 8 3 8 3 n h C y d u t s l n o t v r e s b o r e t n e c e l g n S 9 1 0 2 y l u J 4 4 l t e u J 0 0 1 0 6 0 6 A N A N A N M 1 0 6 0 6 y l t I y d u t s l o r t n o c e s c d e z m o d n r e v t c e p s o r P 9 1 0 2 h c r M l t e t t e r C 0 0 1 4 2 4 2 e h t r o f s e n l e d u g n e r o K e h T A N 5 7 0 5 M 1 4 2 4 2 e r o K l r t l c n l c d e l l o r t n o c 0 0 1 7 1 1 7 1 1 c t s o n g d I I S W E D S O F T e h T 2 4 5 7 7 4 7 1 0 2 r e t r c 6 7 0 8 6 M 3 s e y e s e y e 7 1 1 7 1 1 y r d f o t n e m e g n m d n s s o n g d 9 4 4 1 0 2 e y e 0 5 5 0 2 4 1 I D S O A N s e y e e r o K l r t l c n l c d e l l o r t n o c h c o r p p d n l b e l b u o d d e z m o d n R 5 4 d e z m o d n r e v t c e p s o r P r e b m e t p e S 6 4 l t e n u J 9 1 0 2 d e z m o d n r e v t c e p s o r P r e b o t c O l t e n o o Y 9 1 0 2 8 4 3 7 8 5 7 M 1 5 5 5 5 n p S y d u t s l n o t n e v r e t n e v t c e p s o r P y r u n J l t e r o m Z s e y e 0 2 0 2 0 5 1316 Ophthalmol Ther 2022 1113091332 6 9 4 A N A N g n t s x e e r P D E D D E D f o n o t n ﬁ e D x e S F M 0 4 8 2 0 c t s o n g d I I S W E D S O F T e h T 9 7 1 7 4 7 1 0 2 r e t r c 5 0 1 5 1 1 7 5 A N 2 6 3 5 D S n e m r e t f e m t e z s e g A p u w o l l o F e l p m S y r t n u o C e p y t y d u t S n o t c l b u P e c r u o S e t d d e u n t n o c 2 e l b T 2 8 5 4 7 2 9 1 3 5 6 t c r t c y r e g r u s M 3 M 1 s e y e 4 8 2 4 8 2 s e y e 5 1 1 5 1 1 n h C y d u t s e v t c e p s o r P y r u n J 2 5 l t e u Q 0 2 0 2 9 1 0 2 1 5 y l t I y d u t s l n d u t g n o l l n o t v r e s b o r e t n e c e l g n S r e b m e c e D l t e n l l V 6 1 7 4 2 7 6 8 4 6 0 0 2 r e t r c c t s o n g d e s e n p J e h T 6 2 1 4 3 8 9 5 7 M 3 7 6 7 6 n p J y d u t s l o r t n o c e s c l n o t v r e s b o e v t c e p s o r P 0 2 0 2 e n u J o r u k u b m h S s e y e 6 5 l t e 4 2 s e y e 5 5 l t e A N 6 0 0 2 r e t r c c t s o n g d e s e n p J e h T 2 3 7 5 n m 5 m m 5 1 4 0 1 3 9 6 M 2 1 9 8 9 8 n p J y d u t s l n o t v r e s b o l n o t c e s s s o r C 0 2 0 2 l r p A d u y n H s e y e y d u t s e v t c e p s o r p 4 5 l t e t s e t r e m r h c S d n 7 T U B F T 5 1 0 3 8 4 7 w 2 5 4 5 4 y l t I d e z m o d n r l e b l n e p o g n t e k r m e r p r e t n e c t l u M 0 2 0 2 h c r M l o o n g g o F A N 6 1 8 1 9 2 1 6 4 6 M 1 2 6 2 6 n r I l r t l c n l c d n l b e l p r t d e z m o d n R r u r b e F d R h o o k o h S s e y e 0 2 0 2 3 5 l t e Ophthalmol Ther 2022 1113091332 1317 t s o P A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N A N 1 0 3 0 1 0 3 0 4 2 5 8 5 0 3 4 4 3 6 9 9 9 3 2 1 4 3 7 9 5 0 1 5 0 1 4 1 8 0 1 2 4 3 9 9 8 0 7 0 0 9 8 1 1 3 1 6 1 A N A N A N A N A N A N A N A N A N A N A N A N 7 0 0 0 1 1 1 4 4 0 1 5 4 4 6 1 4 2 8 3 0 0 1 0 1 2 4 7 0 4 0 4 0 3 1 8 0 4 0 9 1 2 4 5 0 5 1 6 1 0 9 3 4 1 4 6 5 6 6 4 2 A N A N A N A N 0 1 0 7 6 1 2 1 1 V O T e r P A N t s o P A N H M T e r P A N t s o P 7 5 7 e r P 1 4 1 I r e m r h c S n e m m e h c s m e h c s I I e d r g I e d r g n e m d r o f x O e h T d r o f x O e h T t s o P S F C e r P t s o P 6 4 T U B F T e r P 2 2 1 t s o P 9 3 3 I D S O e r P 6 2 1 n w u s t e s K 0 2 l t e s n o t n m x e e y e y r D e c r u o S d e u n t n o c 2 e l b T A N A N A N 1 0 3 0 1 0 3 0 0 0 4 0 1 0 2 0 7 6 3 8 3 6 3 7 A N A N A N A N 4 0 1 0 2 0 0 0 4 7 4 9 6 0 7 0 5 0 4 0 0 4 6 4 8 2 0 5 9 4 8 8 8 5 7 3 2 9 6 6 7 1 5 0 8 0 5 0 8 0 6 2 4 9 8 0 1 1 0 1 8 3 9 1 8 5 1 0 1 0 9 3 0 2 1 6 5 2 A N A N 4 6 1 5 6 1 6 9 1 6 3 3 4 1 5 1 0 3 7 5 6 2 0 7 4 0 5 1 5 0 7 3 8 0 0 1 2 2 5 4 4 0 2 4 A N A N l t e k r P 3 1 0 4 2 6 1 7 1 3 7 1 2 5 4 3 9 2 l t e e e L 7 2 A N A N A N l t e e k y M 0 3 A N l t e o t K l t e s e M 5 2 6 l t e u Y z e l z n o G l t e m K 6 2 9 1 0 3 7 6 A N A N l t e n H 5 1 6 3 0 7 2 7 1 8 7 5 9 1 3 2 7 1 1 0 1 0 7 3 2 7 1 1 2 2 l t e e e J 7 1 l t e y k n t e C 1 2 7 1 6 2 1 6 2 1 6 1 A N A N A N r d n e v e D 3 2 l t e A N l t e u h S A N A N A N A N A N 7 2 4 7 6 3 2 7 0 6 7 2 1 9 1 9 1 1 1 5 0 6 2 4 5 5 6 2 9 6 3 1 9 6 2 0 0 1 8 8 l t e u f u s u Y 2 3 1 3 1318 Ophthalmol Ther 2022 1113091332 t s o P A N A N A N A N A N A N A N 9 4 1 8 1 1 3 A N A N A N A N 0 1 1 5 2 9 2 V O T e r P A N A N A N t s o P A N A N A N A N A N A N A N A N 1 0 2 0 e r P A N A N A N A N A N 1 0 4 0 H M T I r e m r h c S t s o P e r P 5 3 8 4 1 9 9 2 1 9 4 5 9 4 2 6 0 1 7 3 1 6 3 9 4 3 1 3 3 2 7 0 4 4 9 1 5 1 2 1 0 3 A N A N A N A N A N A N A N A N 5 3 9 1 1 4 9 8 5 1 1 2 6 6 4 3 6 1 1 5 0 1 4 3 1 A N 9 4 4 9 0 1 7 0 2 1 2 1 2 2 3 5 0 2 9 6 1 0 1 5 2 0 5 2 5 7 1 2 4 5 3 5 1 1 3 1 4 5 1 8 4 1 0 1 6 1 1 2 9 3 1 3 7 4 9 2 1 A N A N A N A N A N A N A N A N l t e n n j S 1 1 1 8 2 1 0 1 1 6 0 5 3 4 0 5 0 8 1 l t e o h S 0 4 0 1 3 1 7 0 6 0 0 1 2 1 2 0 0 1 2 0 4 0 A N A N A N A N 8 6 0 1 1 1 7 5 1 1 A N A N 2 1 4 4 2 1 7 0 1 6 1 1 4 A N A N A N A N l t e t n o t N 1 4 A N l t e s n s k l E 2 4 A N l t e g n o S t s o P A N A N S F C e r P A N A N 2 2 3 4 6 2 4 5 7 6 4 0 4 6 3 6 3 2 A N A N A N 0 2 8 6 1 T U B F T t s o P e r P t s o P I D S O e r P s n o t n m x e e y e y r D e c r u o S d e u n t n o c 2 e l b T 1 2 1 4 5 9 2 A N A N A N 1 0 4 0 A N A N A N A N A N A N A N A N A N A N A N A N A N A N 1 0 3 0 6 2 4 3 1 2 3 9 2 1 2 1 1 4 7 0 9 0 2 1 1 8 A N A N 4 0 4 0 5 0 7 0 7 1 8 4 5 5 5 7 1 1 2 4 8 9 2 1 4 4 1 8 2 1 0 1 2 1 6 6 0 1 6 7 5 1 1 5 0 3 0 A N A N 4 0 2 0 9 2 2 8 6 3 1 9 1 1 1 1 6 0 8 0 4 1 7 3 4 0 3 0 7 1 1 2 9 1 3 3 7 2 6 6 8 1 6 4 6 2 1 3 1 2 0 9 3 2 2 2 2 1 3 0 3 8 8 6 6 5 3 1 6 6 9 5 1 2 7 1 1 7 2 1 5 0 1 1 A N A N A N A N A N A N A N A N l t e n l l V 1 5 3 3 l t e u C 4 3 l t e e H l t e o h C 5 3 l t e l h o K 7 3 4 4 l t e u J l t e t t e r C 5 4 6 4 l t e n u J l t e n o o Y 8 4 l t e r o m Z 0 5 3 4 Ophthalmol Ther 2022 1113091332 1319 t s o P A N A N V O T e r P A N A N t s o P A N H M T e r P A N 7 9 5 0 2 8 4 9 2 1 t s o P e r P I r e m r h c S 4 2 4 5 2 2 9 4 y r t e m o c s n e M A N A N 7 1 6 0 3 7 1 5 0 3 A N A N 8 6 1 5 8 1 t s o P 5 1 A N A N S F C e r P A N 0 A N t s o P e r P T U B F T 0 5 A N 1 1 2 1 A N A N A N A N A N A N A N A N A N A N A N 2 6 3 8 A N A N 6 0 2 0 5 0 2 0 9 1 8 3 3 1 0 6 7 0 8 7 7 1 1 4 6 1 6 0 A N 7 2 7 5 D E D f o n o t r u D y t r e v e s f o k e P y r e g r u s t c r t c r e t f e c n e l v e r p D E D s n o t n m x e e y e y r D e c r u o S d e u n t n o c 2 e l b T t s o P A N I D S O e r P A N 2 5 l t e u Q 6 9 1 8 0 2 2 7 1 0 8 1 d R h o o k o h S 3 5 l t e 2 1 6 1 8 4 1 l o o n g g o F A N A N A N d u y n H 5 5 l t e A N o r u k u b m h S 6 5 l t e 4 5 l t e e c r u o S M 3 M 2 M 3 M 3 M 2 M 2 M 1 A N M 3 M 2 M 3 M 2 M 2 M 1 w 1 M 3 M 1 w 1 M 2 d 0 1 w 1 A N M 1 d 1 M 1 M 1 M 1 w 1 D E D g n t s x e e r p t u o h t w 8 9 2 9 9 0 2 l t e n w u s t e s K 9 2 4 8 2 2 1 7 8 3 1 3 2 1 A N A N A N A N A N A N A N A N 3 1 3 1 3 1 1 4 0 0 8 0 3 4 2 A N 7 1 l t e y k n t e C 3 2 l t e r d n e v e D 9 1 l t e u h S 6 l t e u Y 1 2 l t e n H 2 2 l t e e e J 5 2 l t e s e M z e l z n o G 6 2 l t e m K 7 2 l t e k r P 9 2 l t e e e L 0 3 l t e e k y M 2 3 l t e u f u s u Y 1 3 l t e o t K 1320 Ophthalmol Ther 2022 1113091332 D E D f o n o t r u D y t r e v e s f o k e P y r e g r u s t c r t c r e t f e c n e l v e r p D E D M 3 M 1 M 3 w 6 M 6 M 3 w 6 M 1 M 3 M 3 M 1 M 3 M 1 M 1 M 3 M 1 M 1 w 2 M 2 1 M 3 w 1 d 1 M 1 w 2 A N w 1 w 1 d 1 M 1 w 1 w 1 M 1 w 1 d 1 M 3 w 1 w 1 w 1 A N M 1 D E D g n t s x e e r p t u o h t w 0 2 3 0 5 6 1 9 8 1 4 7 4 1 A N A N A N A N A N A N A N A N A N A N A N 3 6 7 5 5 2 4 7 2 1 4 8 2 6 3 A N A N A N A N A N d e u n t n o c 2 e l b T e c r u o S 3 3 l t e u C 4 3 l t e e H 5 3 l t e o h C 7 3 l t e l h o K 8 1 l t e n n j S 1 4 l t e t n o t N 2 4 l t e s n s k l E 0 4 l t e o h S 3 4 l t e g n o S 4 4 l t e u J 5 4 l t e t t e r C 8 4 l t e n o o Y 6 4 l t e n u J 0 5 l t e r o m Z 1 5 l t e n l l V 3 5 l t e d R h o o k o h S 4 5 l t e l o o n g g o F 5 5 l t e d u y n H 6 5 l t e o r u k u b m h S 2 5 l t e u Q t s o p x e d n I e s e s D e c f r u S r l u c O I D S O e r n n o t s e u Q n o t c n u F l u s V e t u t t s n I e y E l n o t N 5 2 Q F V I E N e l b c l p p t o n A N e l m M e l m e f F e s e s d e y e y r d D E D g n n t s n e c s e r o u ﬂ l e n r o c S F C h t n o m M k e e w w y d d s e u l v y t r l o m s o r e t V O T t h g e h s u c s n e m r e t H M T e m t p u k e r b m ﬁ l r e t T U B F T e v t r e p o e r p e r p e v t r e p o t s o p Ophthalmol Ther 2022 1113091332 1321 surface abnormalities postoperatively ﬁrst measurement 1 month 22 26 2931 35 43 46 Several studies showed varying persistence DED ocular ranging 2 week 12 months cataract surgery 17 18 20 21 26 29 33 35 40 44 46 51 55 56 58 possibly preceded higher baseline OSDI short TFBUT MGD 1 month postoperatively 35 Corneal denervation higher TFBUT score induced cataract surgery returned baseline levels 13 months surgery 17 59 Jun et al 46 reported preservativefree diquafosol showed better efﬁ cacy meibum quality 1 3 months cataract surgery preserva tivecontaining diquafosol preservativefree hyaluronate Risk Factors Prevention Treatment DED After Cataract Surgery Accurately recognizing individual risk fac tors initiating perioperative intervention critical patients preexisting DED par ticularly signs symptoms This section discusses reported risk factors Table 3 preventioninterven tion strategies Table 4 DED cataract surgery minimal cataract Age Sex Lifestyle Older age female sex associated DED surgery 18 25 30 34 37 55 Notably Kohli et al 37 showed individuals age 60 years worse OSDI Schirmer test results TFBUT CFS TMH 2 weeks postcataract surgery Prolonged exposure visual display terminals particularly developed countries concern increasing global DED prevalence 6166 Villani et al 51 suggested use computers exacerbate DED cataract surgery advising minimal visual display terminal use recovery Comorbidities Systemic Diseases Systemic Medications Psychiatric Conditions The association DED cataract surgery diabetes mellitus reported 51 Sajnani et al 18 evaluated epidemiology persistent postsurgical pain PPP mani fested DEDlike symptoms 6 months postoperatively Autoimmune disorders non ocular chronic pain disorder use anti histamines antireﬂux medication antidepres sants antiinsomnia medication reported risk factors PPP hormone replacement therapy thyroid mal function psychiatric conditions systemic medication reported risk factors postoperative DED 51 anxiolytics 27 50 Preexisting DED Two studies reported correlations preexisting DED DED cataract surgery These studies suggest preexisting DED lead severe DED postopera tively Traditional DED metrics predict DED cataract surgery included TFBUT 30 35 51 higher CFS 30 51 conjunc tivochalasis 51 Schirmers I test score 51 TOV 25 Additionally Ocular Surface Frailty Index OSFI developed DED symp tomonset cataract surgery 51 aid predicting ocular surface symptoms OSFI C 03 Lidparallel conjunctival folds ocular allergy predicted DED extent 51 MGD MGD affects tearﬁlm stability strongly associated DED 67 accelerated tear evaporation rate subsequent tear hyperhidrosis MGD likely trigger DED development 35 43 51 52 68 Clinically observed MGD aggravated cataract sur gery positive correlation MGD DEDrelated indicators including postop erative TFBUT CFS 52 Conversely Chi 43 shown preoperative nese trial MGD management allow effective optimal alleviation obstructiveMGD DED induced cataract surgery 1322 Ophthalmol Ther 2022 1113091332 Table 3 Risk factors DED cataract surgery Risk factor Country Year Sample size Adjusted odds ratio 95 CI References Age Older Sex Female India Japan 2018 50 50 eyes NA 2020 86 86 eyes 102 097106 Spain 2016 52 52 eyes NA China 2017 149 149 eyes NA Japan 2017 433 433 eyes 315 212467 USA 2018 119 119 eyes 268 120600 Japan 2020 86 86 eyes 290 118717 Systemic diseases Autoimmune disorder USA 2018 119 119 eyes 132 153114 Diabetes Hormone replacement therapy Nonocular chronic pain disorder Italy Italy 2020 284 284 eyes 112 137711 2020 284 284 eyes 336 218829 USA 2018 119 119 eyes 429 101181 Kohli et al 37 Hanyuda et al 55 GonzalezMesa et al 25 He et al 34 Miyake et al 30 Sajnani et al 18 Hanyuda et al 55 Sajnani et al 18 Villani et al 51 Villani et al 51 Sajnani et al 18 Thyroid malfunction Italy 2020 284 284 eyes 165 130699 Villani et al 51 Systemic medications Antihistamine USA 2018 119 119 eyes 622 217178 Antireﬂux medication USA 2018 119 119 eyes 242 104566 Sajnani et al 18 Sajnani et al 18 Systemic medications Italy 2020 284 284 eyes 170 017483 Villani et al 51 Psychiatric conditions Anxiolytic use USA 2018 119 119 eyes 338 111103 Antidepressant use Antiinsomnia medication use 317 131768 528 098285 Sajnani et al 18 Psychiatric conditions Italy 2020 284 284 eyes 225 098625 Villani et al 51 Ophthalmol Ther 2022 1113091332 1323 Table 3 continued Risk factor Country Year Sample size Adjusted odds ratio 95 CI References Preexisting DED Korea 2016 34 48 eyes NA Spain 2020 55 55 eyes NA Short TFBUT Japan 2017 433 433 eyes 396 259606 Korea 2018 116 116 eyes 032 018057 Italy 2020 284 284 eyes 195 108752 Park et al 27 Zamora et al 50 Miyake et al 30 Choi et al 35 Villani et al 51 Higher CFS Japan 2017 433 433 eyes Score 1 2 298 189469 Miyake et al More score 3 482 278835 30 Italy 2020 284 284 eyes 163 087764 Villani et al 51 Others Conjunctivochalasis Italy 2020 284 284 eyes 112 137771 Villani et al 51 Higher Schirmer test score LIPCOF Ocular allergy Ocular Surface Frailty Index 121 113700 152 204807 222 096663 945 474188 TOV C 312 mOsmL Spain 2016 52 52 eyes NA GonzalezMesa et al 25 MGD Korea 2018 116 116 eyes Increased MG dropout 115 Choi et al 35 104126 Low MG oriﬁce obstruction scores 029 011078 Italy 2020 284 284 eyes 188 078582 China 2019 106 106 eyes NA China 2020 115 115 eyes NA Japan Korea Korea Italy 2017 65 65 eyes NA 2015 80 80 eyes NA 2019 117 117 eyes NA 2020 284 284 eyes 108 106756 Villani et al 51 Song et al 43 Qiu et al 52 Kato et al 31 Jee et al 22 Jun et al 46 Villani et al 51 India 2018 50 50 eyes NA Kohli et al 37 Eyedrop NSAID drops Preservative use Topical drugs Surgical techniques Increased effective phacoemulsiﬁcation time 1324 Ophthalmol Ther 2022 1113091332 Table 3 continued Risk factor Country Year Sample size Adjusted odds ratio 95 CI References Femtosecond laser application Increased surgical microscopelight exposure Lifestyle China 2015 137 137 eyes NA China 2018 233 300 eyes NA China 2019 38 38 eyes NA India 2018 50 50 eyes NA Yu et al 6 Shao et al 40 Ju et al 44 Kohli et al 37 Computer use Italy 2020 284 284 eyes 190 082434 Villani et al 51 CFS corneal ﬂuorescein staining CI conﬁdence interval DED dry eye disease LIPCOF lidparallel conjunctival folds OSDI Ocular Surface Disease Index MG meibomian gland MGD meibomian gland dysfunction NA applicable NSAID non steroidal antiinﬂammatory drug TFBUT tear ﬁlm breakup time Preservatives NSAIDs Eye Drops Preservativecontaining topical eye drops intraoperative postoperative use including benzalkonium chloride cause ocular sur face damage stemming epithelial cell injury apoptosis reduced goblet cell density 69 70 Jee et al 22 compared efﬁcacy preservativefree versus preservative containing sodium hyaluronate 01 ﬂuo rometholone 01 eye drops cataract sur group showed gery The preservativefree superior DEDrelated metrics impression cytol ogy ﬁndings goblet cell count tear interleukin 1b tumor necrosis factora levels catalase superoxide dismutase levels 2 months postoperatively Further Korean study reported compared preservative containing diquafosol preservativefree diqua fosol 3 showed better efﬁcacy treating DED cataract surgery 46 topical nonsteroidal Kato et al 31 observed negative effects antiinﬂammatory drugs NSAIDs cataract surgery junctival goblet cell density raising concerns DED prolonged topical NSAID administration Interestingly topical rebami pide widely prevent oral NSAIDin duced gastric mucosal damage 71 counteracts reduction conjunctival goblet cell density induced diclofenac 31 Treatment Selection Adjuvant Therapies Artiﬁcial tears sodium hyaluronate 01 common ﬁrstline treatments DED 66 72 treatments shifting complex effective topical drops 73 Diquafosol tetrasodium solution reportedly effective DED treatment cataract sur gery comparative beneﬁts artiﬁcial tears 01 29 30 33 46 hyaluronate sodium Addition trehalose sodium hyaluronate effectively reduces DED symptoms improves clinical outcomes TFBUT OSDI cataract surgery possibly owing propen sity deep hydration lipid protein sta bilization protection oxidative insult epithelial cell recovery 45 Fogagnolo et al 54 reported improvements TFBUT solution usage OSDI antioxidant 2 weeks pre postoperatively implicating antioxidants surface homeostasis invasions Oral lactoferrin 23 omega3 fatty acid 60 overthecounter supplements established effective adjuvants DED treatment implicated management DED cataract surgery protecting ocular surgical Surgical Techniques Increased duration surgery longer pha coemulsiﬁcation time risk factors postoperative DED compounded increased Ophthalmol Ther 2022 1113091332 1325 Table 4 Prevention treatment DED cataract surgery Treatment Topical eye drops 02 sodium hyaluronate artiﬁcial tears Antioxidant solution Carbomer sodium hyaluronate trehalose Diquafosol tetrasodium 3 Intervention References Postoperative Ntonti et al 41 Postoperative Fogagnolo et al 54 Postoperative Caretti et al 45 Postoperative Cui et al 33 Miyake et al 30 Lee et al 29 Preservativefree 3 diquafosol Postoperative Jun et al 46 Preservativefree sodium hyaluronate 01 ﬂuorometholone 01 Postoperative Jee et al 22 Rebamipide Preoperative MGD treatment Preoperative MGD treatment Intraoperative postoperative treatments Postoperative Kato et al 31 Postoperative Song et al 43 Hydroxypropyl methylcellulose Intraoperative He et al 34 Ophthalmic viscosurgical device Oral adjuvant omega3 fatty acid Oral lactoferrin DED dry eye disease MGD meibomian gland dysfunction microscopic light exposure 37 Further fem tosecond laserassisted cataract surgery reported risk factors DED cataract surgery 6 40 44 74 likely owing injury caused fem periconjunctival tosecond laser suction ring These results suggest light ﬁlters short surgery duration adequate irrigation soft manipulation ocular surface tissue minimize surgeryrelated complications 20 Use ophthalmic viscosurgical device normally prevent intraocular tissue damage cataract surgeryon ocular surface shown protective effects week postoperatively signiﬁcant improvements TFBUT corneal ocular staining score OSDI 48 Administration hydroxypropyl methylcellulose corneal surface Yusufu et al 32 Intraoperative Yoon et al 48 Postoperative Mohammadpour et al 60 Postoperative Devendra et al 23 results improved clinical outcomes related tear ﬁlm ocular surface health 32 DISCUSSION This systematic review metaanalysis comprehensively present DED prevalence cataract surgery included 775 indi viduals articles 6 18 20 23 30 32 37 50 51 We observed 374 95 CI 226523 206775 patients preexisting DED developed DED postoperatively highlighting impor tance perioperative DED management addressing postoperative patient dissatisfaction decreased QOV The global DED prevalence 550 75 inclusion cataract surgery 1326 Ophthalmol Ther 2022 1113091332 related DED expand half global population Thus thorough effective DED assessment perioperative period cataract surgery warranted 8 62 The major mechanisms underlying DED pathogenesis include tearﬁlm instability ocular surface inﬂammation 47 7680 We observed DED cataract surgery weakly strongly associated tear secre tion Schirmers I test TFBUT respectively 22 29 30 35 44 52 Additionally postoper ative upregulation inﬂammatory mediators contributes DED development 27 7781 simultaneously alters subjective percep tion sensitivity ocular surface nerve plexuses 82 This attributed surgical procedure andor preservatives postsurgical eye drops tribute inﬂammation tearﬁlm instability 37 83 84 Larger corneal wounds 84 longer microscopic exposure times 21 37 greater phacoemulsiﬁcation energy 37 increase likelihood DED surgery including persistent decrease conjuncti val goblet cells despite uncomplicated pha coemulsiﬁcation 59 84 cataract changes focused TFBUT patterns MGD closely related DED pathology 35 43 52 Han et al 21 reported sistent MGD cataract surgery accompanying structural patients preexisting MGD A Japanese study 56 surgery patients DED cataract observing random break pattern predominant postoperative period common feature evaporative DED associated MGD 85 There fore owing potential comorbidity MGD preoperatively evaluated patients preexisting DED 21 26 35 52 regardless Additionally investigated risk factors DED cataract surgery consistent characteristics reported epidemiological studies DED elderly 86 Patients traditional DED risk factors 8 6365 present DED cataract surgery preventative measures considered Other nonocular risk systemic diseases factors include systemic medications psychiatric condi tions Notably diabetes mellitus systemic risk factors DED 87 likely affected tear hyperosmolarity tearﬁlm instability resulting dysfunction lacrimal func tional units ocular surface The effects hyperglycemia lacrimal gland func tional unit components systematically transmitted neural connections resulting abnormal tear production composition contribute DED 8 Ultrasonic energy produced phacoemulsiﬁcation cause free radical formation 88 compound damage Although exact remain underlying mechanisms unclear systemic diseases treatments damage conjunctiva lacrimal glands goblet cells peripheral nerve innervations pre disposing affected population DED cataract surgery There recent consensus concomitant role neurogenic stress ocu lar surface inﬂammation DED pathogenesis 8 Additionally DED associated chronic pain conditions alter genetic susceptibility depression 65 89 Patients DED usually present chronic pain syndromes associated increased severity subjective DED symptoms comparable objective ocular surface signs 90 Anxiety disorders usage anxi olytics antidepressants sleep medication associated DED cataract surgery 18 Extrapolating psychogenic effects ocular sensations possible subjective indicators elevated speciﬁc populations required validate hypothesis The rela tionship surgical techniques DED cataract surgery analyzed Studies reported correlation DED examination values microscopic light exposure time 37 phacoemulsiﬁcation energy 37 surgeons strategize minimize factors patients preoperative DED risk factors studies changes Pathological inﬂammatory kinetics preceding DED cataract surgery crucial determining postoperative treat ment management DED severity Ophthalmol Ther 2022 1113091332 1327 cataract surgery tends peak 1 week postoperatively 6 19 20 32 34 4042 44 45 5254 Nota bly numerous studies reported postoperative followups scheduled 1 week 1 month true peak DED symptoms likely lies time period Kasetsuwan et al 20 proposed timeline corneal neu ron regeneration DED symptom exacerba tion 1 postoperative month correlated As new neurite cells emerge stark increase neural growth factors 25 days postoperatively indicative subep ithelial corneal axon regeneration Khanal et al 91 reported alterations corneal neu ronal plexuses postoperative decrease blink rate reduced corneal sensitivity feedback Moreover reported recovery tear functions 1 postopera tive month supporting existence DED peak 1 week 1 month postopera tively Notably result coincides observed increased tear evaporation 1 month postoperatively associated usage benzalkonium chloride preservatives 92 authors 21 26 20 17 DED duration cataract surgery clini cally important Studies reported wide range DED duration 1 months 29 18 1 year 33 35 40 44 46 51 55 56 58 Further studies reported surgeryinduced invasive corneal changes recover 1 3 months 17 59 The longterm effects DED cataract surgery remain unclear patients particularly successful bilateral cataract surgery require followup months While studies needed results consistent followup DED necessary 1 month cat aract surgery Postoperative eye drops carefully selected owing variable efﬁcacy presence preservatives Several studies suggested correlation preservatives DED cataract surgery 22 46 advising preservativefree treatment options surgery recipients Considering multifactorial pathophysiology DED wideranging effects cataract surgery ocular surface addressing DED future strategies cataract surgery require surgeons gain better understanding treatment prevention methods This review limitations First included studies followup period 1 year limited analysis longterm effects Second approxi mately threequarters included articles published Asian countries par tially limits generalizability ﬁndings Third criteria dry eye examination techniques DED diagnosis standardized countries practices included studies showed inconsistencies diagnostic studies standards consider standardization diagnostic criteria generalizability study results inclusion partici pants different ethnic groups longer obser vation periods standardized guidelines DED diagnosis proposed Tear Film Ocular Surface Society 47 Asia Dry Eye Society 76 use Future CONCLUSIONS This study comprehensively analyzed DED prevalence characteristics cataract surgery It presents concise uptodate description risk factors prevention treatments Our ﬁndings contribute generat ing increased awareness physicians researchers general population regard ing DED cataract surgery encourage development effective preventative treatment strategies ACKNOWLEDGEMENTS The authors thank members Depart ment Ophthalmology Juntendo University Graduate School Medicine critical comments manuscript Funding This work supported JSPS KAKENHI Grant Numbers JP20KK0207 Take nori Inomata JP21K20998 Atsuko Eguchi 1328 Ophthalmol Ther 2022 1113091332 The journals Rapid Service Fees funded authors human participants animals performed authors Authorship All named authors meet International Committee Medical Journal Editors ICMJE criteria authorship article responsibility integrity work given approval version published Author Contributions Concept design Takenori Inomata Acquisition analysis interpretation data All authors Drafting manuscript Maria Miura Takenori Ino mata Jaemyoung Sung Critical revision manuscript important intellectual tent All authors Statistical analysis Maria Miura Takenori Inomata Masahiro Nakamura Akie MidorikawaInomata Administrative technical material support Maria Miura Inomata Ken Nagino Akie Mid Takenori orikawaInomata Jun Zhu Keiichi Fujimoto Yuichi Okumura Kenta Fujio Kunihiko Hiro sawa Yasutsugu Akasaki Mizu Kuwahara Atsuko Eguchi Hurramhon Shokirova Supervision Akira Murakami Disclosures Dr Takenori Inomata reported receiving grant Johnson Johnson Vision Care Inc Hogy Medical Co Ltd SEED Co Ltd Santen Pharmaceutical Co Ltd Alcon Japan Ltd Lion Ltd InnoJin Co Ltd personal fees Santen Pharmaceutical Co Ltd submitted work Dr Akira Murakami reported receiving grants Eisai Co Ltd Kowa Ltd Novartis Pharma KK HOYA Cor poration ROHTO Pharmaceutical Co Ltd Alcon Japan Ltd AMO Japan KK Otsuka Pharmaceutical Co Ltd SEED Co Ltd Senju Pharmaceutical Co Ltd Novartis Pharma KK Pﬁzer Japan Inc Santen Pharmaceutical Co Ltd personal fees Johnson Johnson Vison Care Kowa Ltd Lion Ltd outside submitted work No disclosures reported Compliance Ethics Guidelines This article based previously conducted studies contain new studies Data Availability All data relevant study included article Commons Open Access This article licensed Creative AttributionNon Commercial 40 International License permits noncommercial use sharing adaptation distribution reproduction medium format long appropriate credit original authors source provide link Creative Commons licence indicate changes The images party material article included articles Creative Commons licence indicated credit line material If material included articles Creative Commons licence intended use permitted statutory regulation exceeds permitted use need obtain permis sion directly copyright holder To view http creativecommonsorglicensesbync40 licence copy visit REFERENCES 1 2 Pascolini D Mariotti SP Global estimates visual impairment 2010 Br J Ophthalmol 2012965 6148 Foster A Vision 2020 Community Eye Health 20001334179 cataract challenge 3 Hardten DR Dry eye disease patients cat aract surgery Cornea 2008277855 4 5 6 Li XM Hu L Hu J Wang W Investigation dry eye disease analysis pathogenic factors patients cataract surgery Cornea 2007269 Suppl 1S1620 Ram J Gupta A Brar G Kaushik S Gupta A Out comes phacoemulsiﬁcation patients dry eye J Cataract Refract Surg 200228813869 Yu Y Hua H Wu M et al Evaluation dry eye femtosecond laserassisted cataract surgery J Cataract Refract Surg 20154112261423 Ophthalmol Ther 2022 1113091332 1329 7 Inomata T Nakamura M Sung J et al Smartphone based digital phenotyping dry eye P4 medicine crowdsourced crosssectional study NPJ Digit Med 202141171 8 Stapleton F Alves M Bunya VY et al TFOS DEWS II epidemiology report Ocul Surf 201715333465 9 Miura M Inomata T Nojiri S et al Clinical efﬁcacy diquafosol sodium 3 versus hyaluronic acid 0 1 patients dry eye disease cataract surgery protocol singlecentre randomised controlled trial BMJ Open 2022121e052488 10 Okumura Y Inomata T Iwata N et al A review Dry Eye Questionnaires measuring patientre ported outcomes healthrelated quality life Diagnostics Basel 2020108559 relation associated intraoperative risk factors Middle East Afr J Ophthalmol 20152244727 20 Kasetsuwan N Satitpitakul V Changul T Jar iyakosol S Incidence pattern dry eye cataract surgery PLoS ONE 2013811e78657 21 Han KE Yoon SC Ahn JM et al Evaluation dry eye meibomian gland dysfunction catar act surgery Am J Ophthalmol 201415761144 50e1 22 Jee D Park M Lee HJ Kim MS Kim EC Compar ison treatment preservativefree versus pre served ﬂuorometholone 01 eyedrops cataract sur gery patients preexisting dryeye syndrome J Cataract Refract Surg 201541475663 hyaluronate sodium 01 11 Miller KL Walt JG Mink DR et al Minimal clini cally important difference ocular surface disease index Arch Ophthalmol 20101281 94101 23 Devendra J Singh S Effect oral lactoferrin cataract surgery induced dry eye randomised controlled trial J Clin Diagn Res 2015910NC06 9 12 MidorikawaInomata A Inomata T Nojiri S et al Reliability validity Japanese version Ocular Surface Disease Index dry eye disease BMJ Open 2019911e033940 13 Wolffsohn JS Arita R Chalmers R et al TFOS DEWS II diagnostic methodology report Ocul Surf 201715353974 24 Shimazaki J Japan Dry Eye Society Deﬁnition diagnosis dry eye 2006 Atarashii Ganka 2007241814 25 GonzalezMesa A MorenoArrones JP Ferrari D Teus MA Role tear osmolarity dry eye symp toms cataract surgery Am J Ophthalmol 201617012832 14 Moher D Liberati A Tetzlaff J Altman DG Pre ferred reporting items systematic reviews metaanalyses PRISMA statement PLoS Med 200967e1000097 15 Stroup DF Berlin JA Morton SC et al Metaanal ysis observational studies epidemiology proposal reporting Metaanalysis observa tional studies epidemiology MOOSE group JAMA 200028315200812 16 Inomata T Kitazawa K Kuno T et al Clinical prodromal ocular symptoms coronavirus disease systematic review metaanalysis Invest Ophthalmol Vis Sci 2020611029 17 Cetinkaya S Mestan E Acir NO Cetinkaya YF Dadaci Z Yener HI The course dry eye phacoemulsiﬁcation surgery BMC Ophthalmol 20151568 18 Sajnani R Raia S Gibbons A et al Epidemiology persistent postsurgical pain manifesting dry eye like symptoms cataract surgery Cornea 20183712153541 19 Sahu PK Das GK Malik A Biakthangi L Dry eye following phacoemulsiﬁcation surgery 26 Kim JS Lee H Choi S Kim EK Seo KY Kim TI Assessment tear ﬁlm lipid layer thickness Semin Ophthalmol 20183322316 surgery cataract 27 Park Y Hwang HB Kim HS Observation inﬂu ence cataract surgery ocular surface PLoS ONE 20161110e0152460 28 Deﬁnition Classiﬁcation Subcommittee International Dry Eye WorkShop 2007 The deﬁ nition classiﬁcation dry eye disease report Deﬁnition Classiﬁcation Subcommittee International Dry Eye WorkShop 2007 Ocul Surf 2007527592 29 Lee H Kim SM Choi S Seo KY Kim EK Kim TI Effect diquafosol cent ophthalmic solution tear ﬁlm corneal aberrations cataract surgery Clin Exp Optom 20171006 5904 30 Miyake K Yokoi N Inﬂuence ocular surface cataract surgery effect topical diquafosol postoperative dry eye multicenter prospective randomized study Clin Ophthalmol 201711 52940 1330 Ophthalmol Ther 2022 1113091332 31 Kato K Miyake K Kondo N et al Conjunctival goblet cell density following cataract surgery diclofenac versus diclofenac rebamipide randomized trial Am J Ophthalmol 2017181 2636 32 Yusufu M Liu X Zheng T Fan F Xu J Luo Y Hydroxypropyl methylcellulose 2 dry eye prevention phacoemulsiﬁcation senile diabetic patients Int Ophthalmol 2018383 126173 33 Cui L Li Y Lee HS Yang JM Choi W Yoon KC Effect diquafosol tetrasodium 3 junctival surface clinical ﬁndings cataract surgery patients dry eye Int Ophthalmol 2018385202130 34 He Y Li J Zhu J Jie Y Wang N Wang J The improvement dry eye cataract surgery viscosurgical intraoperative ophthalmic devices surface cornea results consortcompliant randomized controlled trial Medicine Baltimore 20179650e8940 35 Choi YJ Park SY Jun I et al Perioperative ocular parameters associated persistent dry eye symptoms Cornea cataract 20183767349 surgery 36 Schiffman RM Christianson MD Jacobsen G Hirsch JD Reis BL Reliability validity Ocular Surface Disease Index Arch Ophthalmol 2000118561521 37 Kohli P Arya SK Raj A Handa U Changes ocular surface status phacoemulsiﬁcation patients senile cataract Int Ophthalmol 2019396 134553 38 Baudouin C Aragona P Van Setten G et al Diag nosing severity dry eye clear practical algorithm Br J Ophthalmol 2014989116876 39 Chalmers RL Begley CG Caffery B Validation 5Item Dry Eye Questionnaire DEQ5 dis crimination selfassessed severity aque ous tear deﬁcient dry eye diagnoses Cont Lens Anterior Eye 20103325560 40 Shao D Zhu X Sun W Cheng P Chen W Wang H Effects femtosecond laserassisted cataract sur gery dry eye Exp Ther Med 201816650738 41 Ntonti P Panagiotopoulou EK Karastatiras G Breyannis N Tsironi S Labiris G Impact 01 sodium hyaluronate 02 sodium hyaluronate artiﬁcial tears postoperative discomfort follow ing cataract extraction surgery comparative study Eye Vis Lond 201966 42 Elksnis E Lace I Laganovska G Erts R Tear osmo larity cataract surgery J Curr Ophthalmol 2019311315 43 Song P Sun Z Ren S et al Preoperative manage ment MGD alleviates aggravation MGD dry eye induced cataract surgery prospective randomized clinical trial Biomed Res Int 20192019110 44 Ju RH Chen Y Chen HS et al Changes ocular surface status dry eye symptoms following femtosecond laserassisted cataract surgery Int J Ophthalmol 201912711226 45 Caretti L La Gloria VA Piermarocchi R et al Efﬁ cacy carbomer sodium hyaluronate trehalose vs hyaluronic acid improve tear ﬁlm instability ocular surface discomfort cataract surgery Clin Ophthalmol 201913115763 46 Jun I Choi S Lee GY et al Effects preservative free 3 diquafosol patients preexisting dry eye disease cataract surgery randomized clinical trial Sci Rep 20199112659 47 Craig JP Nichols KK Akpek EK et al TFOS DEWS II deﬁnition classiﬁcation report Ocul Surf 201715327683 48 Yoon DY Kim JH Jeon HS Jeon HE Han SB Hyon JY Evaluation protective effect oph thalmic viscosurgical device ocular surface dry eye patients cataract surgery Korean J Ophthalmol 201933546774 49 Hyon JY Kim HM Lee D et al Korean guidelines diagnosis management dry eye development validation clinical efﬁcacy Korean J Ophthalmol 2014283197206 50 Zamora MG Caballero EF Maldonado MJ Short term changes ocular surface signs symptoms phacoemulsiﬁcation Eur J Ophthalmol 202030613017 51 Villani E Marelli L Bonsignore F et al The ocular surface frailty index predictor ocular surface symptom onset cataract surgery Ophthal mology 2020127786673 52 Qiu JJ Sun T Fu SH et al A study dry eye cataract surgery MGD patients Int Ophthalmol 2020405127784 53 ShokoohiRad S Javaheri SZH Malekabad FZ Khakshoor H Daluee MK Effects preoperative doses betamethasone acetate 01 dry eye control cataract surgery Indian J Ophthalmol 20206834504 Ophthalmol Ther 2022 1113091332 1331 54 Fogagnolo P Favuzza E Marchina D et al New therapeutic strategy innovative lubricating ophthalmic solution minimizing dry eye disease associated cataract surgery randomized prospective study Adv Ther 2020374166474 55 Hanyuda A Negishi K Tsubota K Ayaki M Persis tently worsened tear breakup time keratitis unilateral pseudophakic eyes long postop erative period Biomedicines 20208477 56 Shimabukuro M Maeda N Koh S Abe K Kobayashi R Nishida K Effects cataract surgery symp toms ﬁndings dry eye subjects preexisting dry eye Jpn J Ophthalmol 202064442936 57 Elksnis E Lace I Laganovska G Erts R Tear osmo larity cataract surgery J Curr Ophthalmol 2019311315 58 Song P Sun Z Ren S et al Preoperative manage ment MGD alleviates aggravation MGD dry eye induced cataract surgery prospective randomized clinical trial Biomed Res Int 201920192737968 59 Taehoon Oh Jung Y Chang D Kim J Kim H Changes tear ﬁlm ocular surface cataract surgery Jpn J Ophthalmol 2012562 1138 60 Mohammadpour M Mehrabi S Hassanpoor N Mirshahi R Effects adjuvant omega3 fatty acid supplementation dry eye syndrome following cataract surgery randomized clinical trial J Curr Ophthalmol 2017291338 61 Uchino M Yokoi N Uchino Y et al Prevalence dry eye disease risk factors visual display terminal users The Osaka Study Am J Ophthalmol 2013156475966e1 62 63 64 65 Inomata T Shiang T Iwagami M et al Changes distribution dry eye disease new 2016 diagnostic criteria Asia Dry Eye Society Sci Rep 2018811918 Inomata T Nakamura M Iwagami M et al Risk factors severe dry eye disease crowdsourced research DryEyeRhythm Ophthalmology 201912657668 Inomata T Iwagami M Nakamura M et al Char acteristics risk factors associated diag nosed undiagnosed symptomatic dry eye smartphone application JAMA Ophthalmol 202013815868 Inomata T Iwagami M Nakamura M et al Asso ciation dry eye depressive symptoms largescale research crowdsourced DryEyeRhythm iPhone application Ocul Surf 20201823129 66 Eguchi A Inomata T Nakamura M et al Hetero geneity eye drop use symptomatic dry eye largescale crowdsourced individuals research DryEyeRhythm application Jpn J Ophthalmol 202165227181 Japan 67 Chan TCY Chow SSW Wan KHN Yuen HKL Update association dry eye disease meibomian gland dysfunction Hong Kong Med J 2019253847 68 Chhadva P Goldhardt R Galor A Meibomian gland disease role gland dysfunction dry eye disease Ophthalmology 201712411sS206 69 Albietz JM Bruce AS The conjunctival epithelium dry eye subtypes effect preserved non treatments Curr Eye Res preserved topical 2001221818 70 Pisella PJ Debbasch C Hamard P et al Conjunc tival proinﬂammatory proapoptotic effects latanoprost preserved unpreserved timolol ex vivo vitro study Invest Ophthalmol Vis Sci 200445513608 71 Arakawa T Watanabe T Fukuda T Yamasaki K Kobayashi K Rebamipide novel prostaglandinin ducer accelerates healing reduces relapse acetic acidinduced rat gastric ulcer Comparison cimetidine Dig Dis Sci 19954011246972 72 Messmer EM The pathophysiology diagnosis treatment dry eye disease Dtsch Arztebl Int 201511257181 Quiz 2 73 Yokoi N Georgiev GA Tear ﬁlmoriented diagnosis tear ﬁlmoriented therapy dry eye based tear ﬁlm dynamics Invest Ophthalmol Vis Sci 20185914Des13des22 74 Mian SI Shtein RM Nelson A Musch DC Effect hinge position corneal sensation dry eye laser situ keratomileusis femtosec ond laser J Cataract Refract Surg 2007337 11904 75 Gomes JAP Azar DT Baudouin C et al TFOS DEWS II iatrogenic report Ocul Surf 201715351138 76 Tsubota K Yokoi N Shimazaki J et al New spectives dry eye deﬁnition diagnosis consensus report Asia Dry Eye Society Ocul Surf 20171516576 77 Heidari M Noorizadeh F Wu K Inomata T Mashaghi A Dry eye disease emerging approaches J Clin Med disease analysis therapy 2019891439 1332 Ophthalmol Ther 2022 1113091332 78 Zhu J Inomata T Shih KC et al Application animal models interpreting dry eye disease Front Med Lausanne 20229 830592 79 Chen Y Chauhan SK Shao C Omoto M Inomata T Dana R IFNgammaexpressing Th17 cells required development severe ocular surface autoimmunity J Immunol 2017199311639 80 Hua J Inomata T Chen Y et al Pathological version regulatory T cells associated loss allotolerance Sci Rep 2018817059 81 Inomata T Hua J Nakao T et al Corneal tissue dry eye donors leads enhanced graft rejec tion Cornea 201837195101 82 Belmonte C Acosta MC Gallar J Neural basis sensation intact injured corneas Exp Eye Res 200478351325 83 Chen YA Hirnschall N Findl O Comparison corneal wetting properties viscous eye lubricant balanced salt solution maintain optical clarity cataract surgery J Cataract Refract Surg 2011371018068 84 Cho YK Kim MS Dry eye cataract surgery associated intraoperative risk factors Korean J Ophthalmol 20092326573 85 Yokoi N Georgiev GA Kato H et al Classiﬁcation ﬂuorescein breakup patterns novel method differential diagnosis dry eye Am J Ophthalmol 20171807285 86 Uchino M Dogru M Yagi Y et al The features dry eye disease Japanese elderly population Optom Vis Sci 20068311797802 87 Zhang X Zhao L Deng S Sun X Wang N Dry eye syndrome patients diabetes mellitus prevalence etiology clinical characteristics J Ophthalmol 2016201617 88 Liu X Gu YS Xu YS Changes tear ﬁlm tear secretion phacoemulsiﬁcation diabetic patients J Zhejiang Univ Sci B 2008943248 89 Vehof J Zavos HMS Lachance G Hammond CJ Williams FMK Shared genetic factors underlie chronic pain syndromes Pain 2014155815628 90 Vehof J Sillevis SmittKamminga N Kozareva D Nibourg SA Hammond CJ Clinical characteristics dry eye patients chronic pain syndromes Am J Ophthalmol 20161625965e2 91 Khanal S Tomlinson A Esakowitz L et al Changes corneal sensitivity tear physiology phacoemulsiﬁcation Ophthalmic Physiol Opt 200828212734 92 Wilson WS Duncan AJ Jay JL Effect benzalko nium chloride stability precorneal tear ﬁlm rabbit man Br J Ophthalmol 197559116679